Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2020

View Archived Issues

Lung changes from Parkinson's disease drug candidates are reversible

Platelets play role in Tylenol toxicity

Hepatic glutaminase 1 targeting reduces steatosis and decreases oxidative stress in NASH models

Chimerix initiates phase II/III study of DSTAT in patients with severe COVID-19

Promising data from compassionate care program of CAP-1002 in critical COVID-19 patients

Phase I data for SNDX-6352 as monotherapy and in combination with durvalumab presented

SVC-112 inhibits tumor growth in HNSCC models

First-in-human data presented for MOv18

Massachusetts General Hospital and collaborators patent SREBF1 inhibitors

Glo Pharma synthesizes new nicotinic acetylcholine receptor antagonists

BAY-2416964: an orally available AhR antagonist for the immunotherapy of advanced solid tumors

New CDK2/cyclin E inhibitors identifies at Incyte

Galecto Biotech presents new galectin-3 inhibitors

Autifony Therapeutics identifies new K(V)3 potassium channel modulators

Reprogramming microglial functional state has therapeutic potential for AD

AZD-9833: an orally available SERD presented by AstraZeneca

Phase II data presented for genolimzumab in peripheral T-cell lymphoma, alveolar soft part sarcoma

First-in-human data presented for TruUCAR-based GC-027

European Commission approves Ruconest to treat HAE attacks in children

Topline data from phase III study of 5- and 10-day dosing regimens of remdesivir in severe COVID-19

Jazz ends enrollment early in phase III trial of defibrotide for prevention of VOD

FDA approves Zejula as first-line maintenance for ovarian cancer regardless of biomarker status

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...